In February the company had announced its plan to separate the unit, which consists of biosciences and diagnostic solutions, ...

The Financial Times reports today that BD (NYSE: BDX) began discussions with competitors for the sale of its Life Sciences ...

Becton Dickinson & Co. closed 10.30% short of its 52-week high of $251.99, which the company reached on February 3rd.

Buy rating initiated! Discover why this medtech leader with strong growth prospects & dividends is worth your attention.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today was named to Fortune's ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment ...

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) was downgraded by StockNews.com from a “buy” rating to a “hold” ...

Becton Dickinson (BDX) announced the first patient treated in an investigational device exemption clinical trial intended to advance BD’s ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BD treated the first subject in the trial with GalaFLEX LITE Scaffold for reducing the recurrence of CC during breast revision surgeries.

The Food and Drug Administration has identified a Class I recall of Becton, Dickinson and Company BD Alaris Systems Manager and BD Care Coordination Engine Infusion Adapters due to reports that ...